REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

GH Max Output Protocol

GH Optimizationadvanced
23
Peptides

4

Avg Daily mcg

3,814

Level

advanced

Added

May 16, 2026

Overview

The GH Max Output Protocol is an advanced-level growth hormone optimization stack that combines four synergistic secretagogues and releasing hormones to maximize pulsatile GH output throughout the day. This is the most comprehensive GH protocol available, designed for experienced users who have already responded well to simpler GH peptide stacks and are seeking elite-level hormonal optimization for muscle growth, fat loss, recovery, and anti-aging. CJC-1295 at 2000mcg three times weekly provides a sustained elevation of baseline growth hormone releasing hormone (GHRH) signaling. As a modified GHRH analogue with extended half-life via Drug Affinity Complex (DAC) technology, it creates a steady amplification of GH pulses over several days per injection, raising the floor from which all other secretagogues operate. Ipamorelin at 300mcg twice daily triggers acute GH pulses by mimicking ghrelin at the pituitary. Its selectivity means clean GH release without unwanted cortisol or prolactin elevation. Twice-daily dosing creates multiple GH spikes that mirror youthful secretion patterns. Tesamorelin at 2000mcg daily is an FDA-approved GHRH analogue that powerfully stimulates anterior pituitary somatotrophs. It provides a strong GHRH signal distinct from CJC-1295, and clinical trials have demonstrated significant reductions in visceral fat and improvements in IGF-1 levels. Sermorelin at 500mcg on a 5-days-on/2-days-off schedule provides additional GHRH stimulation through a slightly different receptor binding profile. The cycling schedule prevents receptor desensitization and maintains pituitary sensitivity. The combined effect of layered GHRH signals (CJC-1295, Tesamorelin, Sermorelin) with a ghrelin-mimetic pulse trigger (Ipamorelin) produces GH output that approaches youthful peak levels while maintaining the natural pulsatile pattern that prevents receptor downregulation. Protocol Notes: Ipamorelin doses should be taken on an empty stomach—morning upon waking and before bed. Tesamorelin and Sermorelin are best administered in the evening. CJC-1295 (with DAC) injection days should be spaced evenly. This stack requires regular IGF-1 and glucose monitoring. It is suited for advanced users over 35 seeking maximum anabolic and recovery support. Typical cycles run 12-16 weeks with comprehensive bloodwork at baseline, mid-cycle, and post-cycle.

Dosing Protocol

CJC-1295

3 times per week

2,000 mcg

per dose

Ipamorelin

Twice per day

300 mcg

per dose

Tesamorelin

Every day

2,000 mcg

per dose

Sermorelin

5 days on/2 off

500 mcg

per dose

Goals & Evidence

Evidence tier:community

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.